Can-Fite BioPharma Licenses Piclidenoson, Projects $325M Income
Ticker: CANF · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Sep 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $325M |
| Sentiment | bullish |
Sentiment: bullish
Topics: licensing-deal, revenue-projection, veterinary-medicine, drug-development
TL;DR
Can-Fite inks $325M deal for Piclidenoson in vet market, revenue set to soar!
AI Summary
On September 24, 2024, Can-Fite BioPharma Ltd. announced that Vetbiolix exercised its option to license Piclidenoson for veterinary osteoarthritis. This agreement projects an income of $325 million for Can-Fite over the next 10 years.
Why It Matters
This licensing deal significantly boosts Can-Fite BioPharma's future revenue projections and validates the potential of their drug Piclidenoson in a new market segment.
Risk Assessment
Risk Level: medium — The projected income is contingent on the successful development and commercialization of Piclidenoson in the veterinary market over a 10-year period, which carries inherent risks.
Key Numbers
- $325M — Projected Income (Over the next 10 years from the Vetbiolix licensing deal.)
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — The company announcing the licensing deal.
- Vetbiolix (company) — The company exercising the option and licensing the drug.
- Piclidenoson (drug) — The drug being licensed for veterinary osteoarthritis.
- $325 million (dollar_amount) — Projected income for Can-Fite BioPharma over 10 years.
- September 24, 2024 (date) — Date of the press release and announcement.
FAQ
What is the specific indication for Piclidenoson being licensed by Vetbiolix?
Piclidenoson is licensed for veterinary osteoarthritis.
What is the duration of the projected income stream from this deal?
The projected income of $325 million is expected over the next 10 years.
Which company is exercising the option to license Piclidenoson?
Vetbiolix is exercising its option to license Piclidenoson.
What is the exact date of the press release announcing this agreement?
The press release was issued on September 24, 2024.
What is the total projected income for Can-Fite BioPharma from this licensing agreement?
Can-Fite BioPharma projects an income of $325 million from this agreement.
Filing Stats: 200 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-09-24 07:05:13
Key Financial Figures
- $325M — ase entitled “Projected Income of $325M to Can-Fite Over the Next 10 Years Afte
Filing Documents
- ea0215472-6k_canfite.htm (6-K) — 9KB
- ea021547201ex99-1_canfite.htm (EX-99.1) — 14KB
- 0001213900-24-081191.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 24, 2024 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 2